Microbiome Sequencing Services Market Size, Share & Trends Analysis Report By Technology (Sequencing By Synthesis, Sequencing By Ligation, Sanger Sequencing), By Application, By End-user, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global microbiome sequencing services market size was valued at USD 1.37 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 10.9% from 2023 to 2030. The key drivers responsible for market growth are the surge in genomics based gut research and the growing demand for Next-generation Sequencing (NGS). The microbiome is a collective term for the bacteria, fungi, viruses, and protists that exist in and on the human body as well as in the surrounding environment. To identify the microbes that make up a particular microbiome, researchers are using metagenomics sequencing, which entails the continuous sequencing of genetic information from different organisms. Microbiome sequencing has the potential to provide cutting-edge techniques for disease diagnosis, treatment, and prognosis, thus it had recently gained prominence in the scientific community. Primarily as a result of the complicated interactions that take place within the microbiome, the introduction of new methodologies, such as NGS and bioinformatics algorithms, has led to a paradigm shift in the areas of clinical microbiology as well as infectious diseases.

During the COVID-19 pandemisc, there was an increase in microbiome sequencing and research to study more about how viruses influence human health and to be prepared for future diseases. It had a relatively positive impact on the microbiome sequencing services market across the globe. However, as the situation has improved globally, the market has once again resumed its previous course. The SARS-COV-2 outbreak is fueling a huge gathering of research capacity that has accelerated adoption of the Genome sequencing in order to meet the imperative challenge of monitoring variations inside the SARS-CoV-2 genome in an effort to stop the virus spread and track the effectiveness of the vaccine.

Several research institutes are developing advanced tools for the improvement of microbiome sequencing analysis and to encourage researchers, this growing innovation will contribute to the market growth during forecast years. For instance, in May 2022, Texas Biomedical Research Institute in collaboration with Tulane University researchers developed an innovative software tool that makes it simpler, quicker, and more affordable to evaluate genetic data about a host and its microbiome simultaneously in time. A wide variety of drug developers and microbiologists, who study diseases like cancers, COVID-19, HIV/AIDS, malaria, and numerous other human medical conditions related to microorganisms, can use the software, called a meta-transcriptome detector (MTD).

Similarly, the Chinese Academy of Sciences (CAS) supported a research team from the Qingdao Institute of Bioenergy and Bioprocess Technology (QIBEBT) in January 2022 to create a low-cost metagenome sequencing technology. This technology enables high-resolution viewing of the entire "landscape" of species present in a microbiome, even in samples with low levels of biomass, damage, or contamination. Due to the development of cost-effective solutions and with a steady reduction in the costs of testing, the penetration rate of microbiome sequencing services within low-income countries as well as emerging countries is likely to increase. Which in turn is predicted to support the market growth.

Technology Insights

Based on the technology, the sequencing by synthesis segment accounted for a significant share of 57.5% in 2022 and it is also anticipated to be the fastest-growing segment during the forecast period. Sequencing by synthesis (SBS), which has a highly parallel structure that enables the simultaneous sequencing of millions of amplicons, and resulted in a lot of interest in studying bacterial populations in the gut, skin, and other organs, each of which has a distinct microbial fingerprint. Since the sequencing by synthesis (SBS) is an extensively used method and is utilized by several commercial companies, it is expected to boost segmental revenue.

Application Insights

The gastrointestinal disorders segment is dominating the market with a revenue share of 54.0% in 2022. Studying the microbiome can help us better understand a number of gut-related diseases, such as Crohn's disease, diabetes, ulcerative colitis, and gastrointestinal cancers. Thus, the rising incidence of gut-related diseases globally is supplementing the segment revenue. Additionally, the advancement of cutting-edge sequencing technologies to study gut microbiota has also led to an increase in research and development, which contributes to segment growth.

The autoimmune disorder segment is the fastest-growing segment and is expected to witness notable growth at a CAGR of 13.0% by 2030. Since microbial composition alterations can result in the loss of immune tolerance, the human microbiome may play a significant role in autoimmunity. An estimated 3-5% of people globally have autoimmune diseases, which are caused when the immune system attacks one's own tissues. Furthermore, the growing demand for advanced microbiome sequencing services for the early detection of autoimmune diseases and growing awareness among healthcare professionals about these services' availability is expected to expedite segment growth over the forecast period.

End-user Insights

The academic research institutes segment accounted for the largest market share of 43.3% in 2022. The widespread application of microbiome sequencing services for protein, as well as small molecule analysis in research institutions and academics, contributes to the segment's high market share.

The pharmaceutical and biotechnology companies segment is the fastest growing segment and is expected to witness a CAGR of 12.4% by 2030. The demand for this segment is being fueled by factors including the substantial increase in R&D investments as well as the rise in the number of pharmaceutical and biopharmaceutical patents being granted globally.

Regional Insights

North America dominated the market in 2022 with revenue share of 47.85%. The market is expanding as a result of a growing number of cancer incidences in North America. One of the top ten primary causes of death in the US is cancer. For instance, According to the GLOBOCAN 2020 report, there will be roughly 2,281,658 instances of cancer overall in the U.S. in 2020. By 2040, there will likely be 366,572,150 instances, according to estimates. The North America market for microbiome sequencing services is also anticipated to expand due to the increasing need for these services owing to the ease of diagnosis and treatment.

The Asia Pacific region is anticipated to expand at the fastest CAGR of 12.6% over the forecast period due to the presence of major players. Additionally, the industry is growing as more individuals use different sequencing services for diagnosing diseases. Furthermore, growing funding in the countries such as Japan to study the microbiome and the relationship between microbes and disease states is expected to boost the demand for microbiome sequencing services in the Asia Pacific region.

Key Companies & Market Share Insights

The global market is moderately competitive, with several key players. To maintain their market presence, companies operating in this industry are using a variety of strategies, including the introduction of the latest technologies, partnerships, and collaborations, and mergers and acquisitions. For instance, in March 2022, OraSure Technologies, a Diversigen subsidiary, introduced a new service in order to provide gut microbiota sample metatranscriptomic sequencing and analysis. Some of the key players in the global microbiome sequencing services market include:

• Microbiome Insights Inc.

• Baseclear BV

• Clinical-Microbiomics A/S

• Mérieux NutriSciences Corporation

• MR DNA

• Metabiomics Corp.

• Rancho BioSciences

• Second Genome

• Zymo Research Corporation

• uBiome, Inc.

Microbiome Sequencing Services Market Report Scope 

Global Microbiome Sequencing Services Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global microbiome sequencing services market report based on technology, application, end-user, and regions:

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Sequencing By Synthesis

  • Sequencing By Ligation

  • Sanger Sequencing

  • Others

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Autoimmune Disorder

  • Cancer

  • Gastrointestinal Disorders

  • Others

• End-user Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharmaceutical & Biotechnology Companies

  • Academic Research Institutes

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait